Skip to content

Application of novel multimodal endobronchial optical coherent tomography in the Diagnosis of Peripheral lung cancer

Application of novel multimodal endobronchial optical coherent tomography in the Diagnosis of Peripheral lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119282
Enrollment
Unknown
Registered
2026-02-25
Start date
2024-04-08
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Pulmonary Nodules

Interventions

Gold Standard:Biopsy tissue pathology
Index test:O-arm CT, magnetic navigation bronchoscopy, optical coherence tomography technology

Sponsors

Beijing Chao-yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 years and above, and 75 years and below, gender not restricted; 2. Chest CT shows peripheral lung lesions and a suspected diagnosis of peripheral lung cancer, requiring biopsy; 3. Chest CT of the patient indicates that the lesion to be biopsied is located in the bronchus below the segment; 4. The patient voluntarily agrees to undergo bronchoscopy and meets the requirements for bronchoscopy; 5. The patient can understand the purpose of the trial, has good compliance with the received examination and follow-up, voluntarily participates in this research project, and signs the informed consent form. 6. The maximum diameter of the lesion to be biopsied is >= 1 cm.

Exclusion criteria

Exclusion criteria: 1. There are contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina pectoris attack; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmia; uncorrectable bleeding tendency or severe coagulation disorder (such as platelet count < 60×10^9/L), uremia, severe pulmonary hypertension, severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular event; aortic dissection or aortic aneurysm; multiple pulmonary bullae; extreme general debilitation; 2. Women who are breastfeeding or pregnant, or those who are planning to conceive; 3. Patients with electromagnetic active implant devices in their bodies; 4. Patients who are allergic to anesthetics; or have a history of multiple severe allergic reactions, or a history of hereditary anaphylaxis; 5. Other situations that the investigator deems unsuitable for participation in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Diagnostic yield;

Secondary

MeasureTime frame
Incidence of complications;

Countries

China

Contacts

Public ContactWang Feng

Beijing Chao-yang Hospital, Capital Medical University

tad2008@hotmail.com+86 10 5201 1260

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026